Navigation Links
Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
Date:3/10/2008

DALLAS, March 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its management team has scheduled a conference call for March 13, 2008 at 10:00 a.m. ET to update the financial community about the status of its clinical trial programs as well as its business opportunities.

Interested parties may participate in the call by dialing (877) 407-8293; callers outside the U.S. may participate by dialing (201) 689-8349 about 5-10 minutes prior to 10:00 a.m. ET. The conference call will also be available on replay starting at 12:00 noon ET on March 13, 2008, and ending on April 13, 2008. For the replay, U.S. participants please dial (877) 660-6853 (replay account # 294, replay conference #278416). The access number for the replay for callers outside the U.S. is (201) 612-7415 (replay account # 294, replay conference # 278416).

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM) -- mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additiona
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
2. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
3. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
4. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
5. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... for solid tumor cancers, announced today that the $17.5 ... 2014, has closed.  The three-year notes have a 5% ... of common stock.  The investors also have an option, ... additional 30% of these notes on the same terms. ...
(Date:8/19/2014)... Aug. 19, 2014  Tokyo-based Atonarp Inc. announced ... round led by Walden Riverwood Ventures with participation ... of Atonarp,s Smart Spectrometer technology platform, which will ... has targeted the oil & gas and healthcare ... are excited to partner with Atonarp in pursuing ...
(Date:8/19/2014)... 19, 2014 Avizia, Inc., a leading provider ... closed an equity financing round led by NextGen Angels ... new funding will be used to continue to fuel ... Avizia welcomes Edward Kennedy , CEO and president ... joins Leonard Kurtzman , CFO of newBrandAnalytics, who ...
Breaking Medicine Technology:NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Avizia Closes Funding Round 2
(Date:8/20/2014)... “Have you recently been involved in an auto accident?” asks ... the greater Seattle area. “Are you still feeling the physical ... . , In a recently released article, Dax Jones asks ... use to see if they may qualify for a personal ... will allow an individual to receive medical treatment for their ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers,restraints, challenges, opportunities, current market trends,and strategies ... the estimates and forecasts of the revenue and ...
(Date:8/20/2014)... 20, 2014 Mixberry Media announced today ... websites and create a new source of revenue. , ... by listening to a narration of their favorite news ... and languages. Users can now multitask: read/write email, ... while consuming content. , Mixberry Media’s service ...
(Date:8/20/2014)... Astoria, New York (PRWEB) August 20, 2014 ... to the Global Bureau of Disease, low back pain is ... of the most common reasons for missed work. Americans spend ... of this pain. , Most cases of back pain are ... a mechanical (non-organic) origin. , For example, Pete, a busy ...
(Date:8/19/2014)... 20, 2014 Midtown Dentistry in Houston, Texas, ... office. All patients with cavities, or with old fillings ... fillings that can safely repair and restore teeth. , From ... latest materials, all of which are completely amalgam free. Even ... use by the FDA for adults and children over the ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... , , WASHINGTON , Jan. 13 ... and Bruce A. Mrusek , a resident of Maineville, Ohio , ... Judge Michael R. Barrett in Cincinnati , the Justice Department ... both dentists, wer e i n d ...
... say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... tendon doesn,t appear to be effective, a new study ... plasma (PRP) injections are no better than placebo in ... active. , The study included 54 patients, aged 18 ...
... And rates among boys aged 6-19 still climbing, government study ... news in the war on weight: Obesity in the United ... studies show. , But the rates of obesity remain high, ... category. And, rates of obesity among already heavy 6- to ...
... researchers have found that six essential oils from thyme, ... COX-2 enzyme, in a manner similar to resveratrol, the ... They also identified that the chemical carvacrol was primarily ... appearing in the January issue of Journal of ...
... ... to provide fully integrated topical clinical phase 1 study services for trials in healthy ... , ... January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership ...
... January 21st ... Understand the Latest Developments in VoIP Fax Capabilities, , ... Tigard, Oregon (Vocus) January 13, 2010 -- FaxBack , the ... the Miami Beach Convention Center. , , , , ,At the show, FaxBack (booth ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 2Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 3
ENDO STITCH™ Single Use Loading Units....
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... ligature inserted into a plastic tube. The plastic tube ... other. The suture protrudes from the narrow end and ... which becomes secure after the device is activated. The ... scored end of the plastic tube. The scored end ...
Medicine Products: